MOSCOW, Dec. 6, 2021 /PRNewswire/ -- The Russian
Direct Investment Fund (RDIF, Russia's sovereign wealth fund) today
announced the Russian one-shot Sputnik Light vaccine against
coronavirus has been approved by the Ministry of Health of
Argentina as a standalone vaccine
and a booster shot.
Sputnik Light vaccine is based on human adenovirus serotype 26
which is the first component of the Sputnik V vaccine.
Argentina was one of the first
countries in the world to authorize Sputnik V in December 2020. The National Administration of
Drugs, Foods and Medical Devices (ANMAT) registered Sputnik V based
on Russian clinical trial data without additional trials in
Argentina. Sputnik V is one of the
main vaccines used during the vaccination campaign throughout the
country, providing for 35 times reduction in new COVID cases during
4 months. Sputnik V has played a decisive role in protecting
population of Argentina and
helping the country to stay among the leaders in the fight against
The one-shot Sputnik Light is also a highly effective vaccine
used both on standalone basis and applied as a booster. Findings by
the Gamaleya Center based on data from 28,000 subjects in
Moscow have demonstrated Sputnik
Light vaccine administered standalone has 70% efficacy against
infection from the Delta variant of coronavirus during the first
three months after vaccination. The vaccine is 75% effective among
subjects under the age of 60.
Efficacy of one-shot Sputnik Light as a booster against Delta
variant for other vaccines will be close to the efficacy against
the Delta variant of the Sputnik V vaccine: over 83% against
infection and over 94% against hospitalization.
Sputnik Light has been proven to be safe and highly effective by
real-world vaccination data. In particular, the vaccine has
demonstrated efficacy of between 78.6-83.7% among the elderly as
confirmed by the Ministry of Health of Buenos Aires, Argentina.
Moreover, a study in Argentina
on heterogeneous regimens combining Sputnik Light and vaccines
produced by AstraZeneca, Sinopharm, Moderna and Cansino has
demonstrated Sputnik Light is an effective universal booster. Each
"vaccine cocktail" combination with Sputnik Light provided higher
antibody titer on 14th day after administering the second dose as
compared to original homogenous (same vaccine as first and second
dose) regimens of each of the vaccines.
The data also demonstrated high safety profile of using Sputnik
Light in combinations with all other vaccines with no serious
adverse events following the vaccination in any combinations. The
study provides the strongest scientific evidence to date supporting
the mix-and-match approach with 5 vaccines involved.
Paraguay's Ministry of Health
found Sputnik Light to be 93.5% effective during the country's
ongoing vaccination campaign.
A one-shot vaccination regimen of Sputnik Light has a number of
key advantages, including ease of administering the vaccine,
monitoring and more flexible re-vaccination schedule when used as a